Brailovski, E., Wu, X., Gallagher, G., Gönen, M., Staron, A., Janardan, A., Sanchorawala, V., Wanjiku, C., Tuchman, S., Piteo, A., Zonder, J., Chung, A., Jimenez-Zepeda, V., Comenzo, R., Landau, H. (2025). Effectiveness of second-line therapies following upfront daratumumab plus bortezomib, cyclophosphamide and dexamethasone: A new benchmark. Blood. https://doi.org/10.1182/blood-2025-5746